Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $29 Analysts' Targets Stanford Group Company $34 Buy Wednesday, July 02, 2008 Needham & Co. $24 Buy Tuesday, July 01, 2008 Robert W. Baird & Co. $28 Outperform Tuesday, January 15, 2008 Cubist Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products that address medical needs in the acute care environment in the Untied States, the European Union, Argentina, Canada, India, Israel, Korea, and Taiwan. The company focuses on developing products for the anti-infective marketplace. It offers CUBICIN, a once-daily, bactericidal, and intravenous antibiotic for the treatment of skin and skin structure infections, caused by Staphylococcus aureus (S. aureus) and other gram-positive bacteria, as well as for blood-stream infections, including right-sided infective endocarditis, caused by methicillin susceptible and methicillin resistant S. aureus. The company also engages in developing compounds for infections caused by resistant gram-negative pathogens. It has various anti-infective programs approaching the IND filing stage preparatory to clinical trials. The company’s product pipeline includes pre-clinical programs that address medical needs in gram-positive infections, gram-negative infections, clostridium difficile-associated diarrhea, and hepatitis C infections. It has a development and supply agreement with Hospira Worldwide, Inc. Cubist Pharmaceuticals was founded in 1992 and is headquartered in Lexington, Massachusetts.
$19.41 (07/12/08)
